PD-1/PD-L1 抑制剂联合应用：克服肿瘤免疫治疗弱点的前景（综述）。

A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).

机构信息

Integrated Traditional Chinese and Western Medicine Laboratory, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.

State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.

出版信息

Mol Med Rep. 2021 May;23(5). doi: 10.3892/mmr.2021.12001. Epub 2021 Mar 24.

DOI:10.3892/mmr.2021.12001

PMID:33760188

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7985997/

Abstract

Programmed cell death protein‑1 (PD‑1)/programmed death protein ligand‑1 (PD‑L1) inhibitors for treatment of a various types of cancers have revolutionized cancer immunotherapy. However, PD‑1/PD‑L1 inhibitors are associated with a low response rate and are only effective on a small number of patients with cancer. Development of an anti‑PD‑1/PD‑L1 sensitizer for improving response rate and effectiveness of immunotherapy is a challenge. The present study reviews the synergistic effects of PD‑1/PD‑L1 inhibitor with oncolytic virus, tumor vaccine, molecular targeted drugs, immunotherapy, chemotherapy, radiotherapy, intestinal flora and traditional Chinese medicine, to provide information for development of effective combination therapies.

摘要

程序性细胞死亡蛋白 1（PD-1）/程序性死亡蛋白配体 1（PD-L1）抑制剂治疗各种类型的癌症已经彻底改变了癌症免疫疗法。然而，PD-1/PD-L1 抑制剂的反应率较低，仅对少数癌症患者有效。开发一种抗 PD-1/PD-L1 敏化剂以提高免疫疗法的反应率和效果是一个挑战。本研究综述了 PD-1/PD-L1 抑制剂与溶瘤病毒、肿瘤疫苗、分子靶向药物、免疫疗法、化疗、放疗、肠道菌群和中药的协同作用，为开发有效的联合治疗方法提供信息。